English

RLS GLOBAL AB (publ) INTERIM REPORT, Q2, 2021

Report this content

APRIL 1st – JUNE 3Oth

  • Net sales amounted to TSEK 244 (TSEK 739)
  • Earnings before interest and taxes (EBIT) amounted to MSEK 8,5 (MSEK -5,6)
  • Other income TSEK 15 429 (TSEK 281)
  • Earning per share before dilution at SEK SEK 0,13 (SEK-0,09)
  • Cash flow from operating activities amounted to MSEK -6,280 (MSEK-5 472)
  • Liquid assets at the end of the period MSEK 6,9 (MSEK 30,3)
  • Equity ratio was 87% (91%)

JAN 1st – JUNE 3Oth

  • Net sales amounted to TSEK 302 (TSEK 1 112)
  • Earnings before interest and taxes (EBIT) amounted to MSEK 2,2 (MSEK-9,5)
  • Other income TSEK 15 429 (TSEK 281)
  • Earning per share before dilution at SEK 0,03 (SEK -0,14)
  • Cash flow from operating activities amounted to MSEK -12,1 (MSEK -10,9)
  • Liquid assets at the end of the period MSEK 6,9 (MSEK 30,3)
  • Equity ratio was 87% (91%)
     

SUMMARY OF EVENTS DURING SECOND QUARTER

  • RLS arranged AGM on June 17.
  • RLS signed a global distribution agreement with ConvaTec.
  • ChloraSolv is regulatory approved for sale in Kuwait.
  • ChloraSolv01 is published in Journal of Wound Care.
 

COVID-19

  • In the current situation, the Board has considered the impact of different possible future covid-19 related scenarios in order to be prepared for future outcomes.

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

The Interim Report Q, 2021 is enclosed and is also available here.

PUBLICATION
This information was submitted for publication through the agency of the above contact person, at 09.00 CET on July 16th, 2021.


 

CONTACT INFORMATION

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Tags:

Life Science RLS medtech chlorasolv RLS Global

Subscribe

Documents & Links